Larimar reports Q3 2026 results, confirms BLA submission and 2027 launch targets
The company's finalized BLA filing for nomlabofusp set accelerated approval timelines, while cash stood at $128.7 million with runway into late Q2 2027.
SEC filing (2)
3 stories
The company's finalized BLA filing for nomlabofusp set accelerated approval timelines, while cash stood at $128.7 million with runway into late Q2 2027.
SEC filing (2)
The board's appointment, effective September 29, 2026, comes with a $560,000 base salary, a $35,000 signing bonus, and inducement equity grants.
SEC filing
The iPSC-derived cell therapy company appointed the iECURE CEO effective September 9, 2026, expanding its board to seven members.
SEC filing